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International Pediatric ORL Group (IPOG)

Hearing Loss in the Pediatric Patient Consensus Recommendations

Consensus Objectives
To make recommendations on the routine work-up for pediatric patients with hearing loss
Target Population
All infants with hearing loss identified by newborn hearing screening and older children with concerns
for hearing loss
Intended Users
These consensus recommendations are targeted for:
1. Primary care providers and otolaryngologists who take care of children with hearing loss.
Recommendations and Justification
The recommendations are outlined in the following sections






Section 1: Diagnostic evaluation considerations
Section 2: Newborn screening and initial workup of the patient with hearing loss
Section 3: Workup of child with auditory neuropathy spectrum disorder (ANSD)
Section 4: Workup of child with sensorineural hearing loss
Section 5: Workup of child with conductive or mixed hearing loss

Disclaimer
This report has been prepared by the members of the International Pediatric ORL Group (IPOG).
Consensus recommendations are based on the collective opinion of the members of the group. Any
person seeking to apply or consult the report is expected to use independent medical judgment in the
context of individual patient and institutional circumstances.

Section 1: Diagnostic evaluation considerations
The members of the IPOG identified six frequently debated considerations in the management of
pediatric hearing loss. Variation in practice among the current group members remains, and the purpose
of this section is to provide a list of reasonable options based on expert opinion.
Question
1. Which children should be
offered genetic testing?








2.

Should temporal bone imaging
be performed?





3.
4.

Should ophthalmology consult
routinely be ordered?
Should cardiology consult be
routinely requested?





5.

Should amplification be
offered for single sided hearing
loss?






6.

Should testing and treatment
for CMV be considered?






After an audiogram, comprehensive genetic testing has the highest
diagnostic rate of any single test for bilateral sensorineural hearing
loss.1
Children with unilateral hearing loss should not be offered genetic
testing.
Single gene testing is of low diagnostic yield and should not be
offered as part of an initial workup.
Directed genetic testing may be considered in consultation with a
geneticist if comprehensive genetic testing is negative but suspicion
for a genetic cause still exists.
Comprehensive genetic testing should be offered to children with
ANSD.
Temporal bone imaging is of low diagnostic yield in all children.
Children who are cochlear implant candidates with profound hearing
loss may benefit from CT or MRI to assess for cochlear dysplasias and
cochlear nerve aplasia.
Temporal bone imaging is optional in unilateral hearing loss and in
children with ANSD.
Given the 2-3 fold increased risk of ocular abnormalities in children
with nonsyndromic SNHL, ophthalmology evaluation is warranted.
Genetic testing may identify children who should have a cardiac
workup. .
Cardiology consult should not be ordered at the onset of diagnosis of
hearing loss.
Children with single-sided hearing loss are at a higher risk for delays
in speech and language development and decreased academic
performance relative to normal hearing peers.
The decision to amplify unilateral hearing loss is complex and
involves factors such as the severity of the hearing loss and
socioeconomic factors such as financial resources.
At minimum, a discussion regarding the benefits of amplification
should be undertaken.
Congenital CMV causes up to ¼ of all congenital sensorineural
hearing loss.2
CMV saliva/urine PCR is highly specific in the first three weeks of life.
Blood spot CMV testing can be used as an adjunct diagnostic test
after the first three weeks of life.
Treatment for CMV associated hearing loss currently only indicated
for symptomatic CMV disease. Treatment with valganciclovir may
improve hearing outcomes in children with asymptomatic congenital
CMV infection but not indicated at this time.3

Section 2: Newborn screening and initial workup of the patient with hearing loss
The screening and initial workup algorithm is designed to guide the evaluation of all newborns with
suspected hearing loss based on initial screening methodologies. The algorithm also applies to children
identified later in childhood. Screening protocols recommended herein are generally derived from
consensus recommendations such as those issued by the Joint Committee on Infant Hearing.4 Protocols
may vary slightly between institutions. In general, infants meeting criteria for increased risk for
congenital hearing loss should be screened with both OAEs and an automated ABR. Infants not within
the high risk category can be screened with a two stage procedure that utilizes OAEs alone as the initial
screening test, with an automated ABR for absent or subthreshold OAE responses. A child who fails
screening protocols should undergo a confirmatory ABR.

Section 3: Workup of child with auditory neuropathy spectrum disorder (ANSD)

The diagnosis of auditory neuropathy spectrum disorder (ANSD) is given when otoacoustic emissions
and/or cochlear microphonics are present in the setting of absent or abnormal ABR. Given that 50% of
ANSD has a genetic basis, comprehensive genetic testing should be offered to children in whom ANSD is
identified. Identification of a specific genetic cause may determine candidacy for habilitation options,
including cochlear implantation. Temporal bone imaging is optional in the setting of ANSD and may
reveal abnormalities in up to 2/3 of patients. 5

Section 4: Workup of child with sensorineural hearing loss
Genetic testing has a limited role in the workup of children with a unilateral sensorineural hearing loss
unless syndromic hearing loss (i.e. Branchio-oto-renal syndrome, Waardenburg syndrome) is suspected
based on physical exam and/or family history. Temporal bone imaging should be optional and
discussed with parents at the time of diagnosis. Comprehensive genetic testing should guide
subsequent workup in children with bilateral sensorineural hearing loss. The diagnostic rate is
approximately 40-65%.1 The physical examination and presence of other risk factors will dictate
additional workup needed in the child with negative genetic testing. Asymptomatic congenital CMV is a
significant contributor to congenital hearing loss and may present as mild to profound, unilateral or
bilateral and stable or progressive. Vestibular dysfunction is also possible. Testing for congenital CMV is
not currently standardized but should be considered in children with identified hearing loss. Treatment
is controversial but has been shown to have some benefit.

Section 5: Workup of child with conductive or mixed hearing loss
The management of an effusion in infants is dependent on the age at which it is identified. In a child
who is older than 3 months, a rapid course of action is indicated to ensure that any appropriate
rehabilitation occurs prior to 6 months. For a child under the age of 3 months with purely conductive
hearing loss, the effusion may be observed for a period of 3 months for spontaneous resolution. If the
hearing loss is mixed in nature, then a shorter observation period of 4-6 weeks is appropriate to ensure
that the sensorineural component is appropriately worked up and diagnosed prior to the age of 6
months.
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